TAT-μUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice

Jarrod A. Call, James M. Ervasti, Dawn A. LoweJournal of Applied Physiology 2011 · DOI

TL;DR

This study demonstrates that a novel protein therapy, TAT-μUtrophin (TAT-μUtr), significantly improves the survival and quality of life in a severe mouse model of Duchenne muscular dystrophy (DMD). By enhancing muscle function and activity, TAT-μUtr offers a promising therapeutic avenue for patients suffering from this debilitating genetic disorder.

What Problem Does This Paper Address?

Duchenne muscular dystrophy (DMD) is a devastating genetic disease characterized by the progressive loss of muscle function due to the absence of the protein dystrophin. This deficiency leads to sarcolemma instability, making muscles highly susceptible to injury during contraction. While utrophin can partially compensate for dystrophin's absence in milder models (mdx mice), a more severe model, the dystrophin and utrophin double-knockout (mdx:utr⁻/⁻) mouse, better reflects the profound muscle weakness and shortened lifespan seen in human DMD patients. Current therapeutic strategies aim to restore dystrophin-like proteins to mitigate disease progression. This paper investigates whether TAT-μUtrophin, a previously shown functional substitute for dystrophin in mdx mice, can also alleviate the severe phenotype in the mdx:utr⁻/⁻ double-knockout model.

Methods

The researchers utilized a mdx:utr⁻/⁻ mouse model, which lacks both dystrophin and utrophin. Two groups of these mice were established: one received twice-weekly intraperitoneal injections of TAT-μUtrophin protein, while the control group received sterile phosphate-buffered saline (PBS).

Key assessments included:

  • Survival Analysis: Kaplan-Meier curves were used to compare the lifespan of TAT-μUtr treated mice versus PBS-treated controls.
  • Quality of Life Metrics:
    • Cage Activity: Mice were monitored in activity chambers for 24 hours to quantify ambulatory distance, stereotypic movements (e.g., self-grooming), and active time.
  • Food Consumption: The amount of food consumed by each mouse over a 24-hour period was measured.
  • In Vivo Muscle Function: The plantarflexor muscles (posterior crural muscles) of the hindlimb were assessed for peak isometric torque and susceptibility to eccentric contraction-induced injury. This involved stimulating the sciatic nerve and measuring torque output before and after an injury protocol.
  • Ex Vivo Muscle Function: The extensor digitorum longus (EDL) muscles were isolated and tested for force-generating capacity (twitch, tetanic, eccentric) and susceptibility to injury. Specific force (force normalized to muscle cross-sectional area) was a key metric.

Datasets

Not discussed in the paper. The study utilized a genetically engineered mouse model (mdx:utr⁻/⁻) and standard laboratory chow and water.

Key Insights and Ideas

  • TAT-μUtrophin bridges the gap: The study successfully demonstrates that TAT-μUtrophin can provide functional benefits even in the absence of both dystrophin and utrophin, a more severe disease model than previously tested.
  • Improved quality of life is linked to better foraging: The significant increase in food consumption and cage activity in TAT-μUtr treated mice suggests that improved muscle function directly translates to a better ability to interact with their environment and sustain themselves.
  • Protection against injury is crucial: While baseline muscle strength wasn't dramatically improved, the reduced susceptibility to eccentric contraction-induced injury, both in vivo and ex vivo, is a critical finding. This suggests TAT-μUtr strengthens the muscle's resilience.
  • A potential therapeutic for severe DMD: The combined improvements in survival, activity, and injury resistance strongly support TAT-μUtrophin as a viable therapeutic candidate for patients with severe forms of muscular dystrophy.

Key Results

  • Survival: TAT-μUtr treatment extended the median life span of mdx:utr⁻/⁻ mice by 45% (43.5 days vs. 30.0 days for PBS controls, P < 0.001).
  • Food Consumption: TAT-μUtr treated mice consumed 72% more food (3.1 g/24h vs. 1.8 g/24h, P = 0.002).
  • Cage Activity: Ambulatory distance increased by 81% (364 m/24h vs. 201 m/24h, P = 0.004), and active time increased (232 min/24h vs. 178 min/24h, P = 0.028) in TAT-μUtr treated mice.
  • In Vivo Muscle Function: While maximal isometric torque was not improved, post-injury torque was significantly better in TAT-μUtr treated mice, indicating reduced injury susceptibility.
  • Ex Vivo Muscle Function: Specific tetanic force (a measure of intrinsic muscle strength) was 30% greater in TAT-μUtr treated EDL muscles (8.3 N/cm² vs. 6.4 N/cm², P = 0.026). Specific eccentric force was also significantly higher. Post-injury specific tetanic force was also significantly improved.

Limitations and Future Work

  • Variability in mdx:utr⁻/⁻ lifespan: The authors acknowledge the inherent variability in the lifespan of mdx:utr⁻/⁻ mice due to environmental factors, which can make inter-laboratory comparisons challenging.
  • Stress of handling: The twice-weekly handling for injections may have added stress to the mice, potentially influencing lifespan.
  • Future Directions: The authors suggest further investigation into TAT-μUtrophin's effectiveness in combination with other therapies to achieve additive efficacy. They also propose exploring its effects on muscle recovery and adaptation.

Summary updated

Abstract

Previously, we demonstrated functional substitution of dystrophin by TAT-μUtrophin (TAT-μUtr) in dystrophin-deficient mdx mice. Herein, we addressed whether TAT-μUtr could improve the phenotype of dystrophin and utrophin double-knockout (mdx:utr(-/-)) mice. Specifically, we quantitatively compared survival and quality of life assessments in mdx:utr(-/-) mice receiving TAT-μUtr protein administration against placebo-treated mdx:utr(-/-) mice (PBS). Additionally, skeletal muscles from TAT-μUtr and PBS mice were tested in vivo and ex vivo for strength and susceptibility to eccentric contraction-induced injury. We found the TAT-μUtr treatment extended life span 45% compared with mice administered PBS. This was attributed to significantly increased food consumption (3.1 vs. 1.8 g/24 h) due to improved ability to search for food as daily cage activities were greater in TAT-μUtr mice (e.g., 364 vs. 201 m ambulation/24 h). The extensor digitorum longus muscles of TAT-μUtr-treated double-knockout mice also displayed increased force-generating capacity ex vivo (8.3 vs. 6.4 N/cm(2)) and decreased susceptibility to injury ex vivo and in vivo. These data indicate that the functional benefits of TAT-μUtr replacement treatment extend to the mdx:utr(-/-) double-knockout mouse and support its development as a therapy to mitigate muscle weakness in patients with Duchenne muscular dystrophy.
BibTeX
@article{call2011tat,
  author = {Jarrod A. Call and James M. Ervasti and Dawn A. Lowe},
  title = {{TAT-μUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice}},
  journal = {Journal of Applied Physiology},
  year = {2011},
  doi = {10.1152/japplphysiol.00248.2011},
}
Figure